Publications for Mitchell S. Cairo mitchell_cairo@nymc.edu

NYMC School of Medicine
NYMC School of Health Sciences and Practice
  • Hochberg, J., Oesterheld, J., Militano, O., Klejmont, L., Harrison, L., Nickerson, B., & Cairo, M. (2016). Final phase I results of mitoxantrone in combination with clofarabine in children with refractory/relapsed acute leukemia. Pediatric Blood & Cancer, 63(Suppl S1), S7. doi:10.1002/pbc.25998

  • Hochberg, J., Oesterheld, J., Militano, O., Klejmont, L., Harrison, L., Nickerson, B., & Cairo, M. (2016). Phase I results of mitoxantrone in combination with clofarabine in children, adolescents and young adults with refractory/relapsed acute leukemia. Pediatric Blood & Cancer, 63(Suppl 3), S108. doi:10.1158/1538-7445.AM2016-3203

  • Hochberg, J., Oesterheld, J., Militano, O., Klejmont, L., Harrison, L., Nickerson, B., & Cairo, M. S. (2016). Phase I results of mitoxantrone in combination with clofarabine in children with refractory/relapsed acute leukemia. Cancer Research, 76(14 (Suppl)), 3203. doi:10.1158/1538-7445.AM2016-3203

  • Keever-Taylor, C. A., Weinberg, R., Grossman, B., Shenoy, S., Talano, J. A., Moore, T. B., . . . Cairo, M. S. (2016). Collection and processing outcomes of G-CSF mobilized peripheral blood stem cells (PBSC) collected from parental haploidentical stem cell sickle cell trait donors of patients undergoing CD34 enriched transplantation for higher risk sickle cell disease (IND). Biology of Blood and Marrow Transplantation, 22(3 (Suppl 1)), S383-S384. doi:10.1016/j.bbmt.2015.11.899

  • Lee, S., Yin, C., Shah, T., Ayello, J., Morris, E., van de Ven, C., & Cairo, M. (2016). Ruxolitinib, A JAK1/JAK2 inhibitor, significantly prolongs survival in both primary mediastinal B-cell lymphoma & hodgkin lymphoma xenograft NSG mouse model: A potential targeted adjuvant therapy. Pediatric Blood & Cancer, 63(Suppl 3), S10.

  • Lee, S., Yin, C., Shah, T., Ayello, J., Morris, E., Van De Ven, C., & Cairo, M. S. (2016). Upregulation of DLEU1 significantly prolongs survival in a rituximab-treated DLEU1 knockout human Burkitt lymphoma (BL) xenograft NSG mouse model: DLEU1 may act as a tumor suppressor gene in pediatric BL. Cancer Research, 76(14 (Suppl)), 3838. doi:10.1158/1538-7445.AM2016-3838

  • Liao, Y., Ivanova, L., Plumer, T., Morris, E., Gurney, J., Herb, S., . . . Cairo, M. (2016). Potential use of human placental derived stem cells (HPDSCs) as a novel stem cell source for the treatment of recessive dystrophic epidermolysis bullosa (RDSB). Cytotherapy, 18(6), S12. doi:10.1016/j.jcyt.2016.03.031

  • Liao, Y., Ivanova, L., Plumer, T., Morris, E., Karimov, C., Gurney, J., . . . Cairo, M. S. (2016). Potential use of human placenta derived stem cell (HPDSCs) as a novel stem cell source for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Biology of Blood and Marrow Transplantation, 22(3), S422-S423. doi:10.1016/j.bbmt.2015.11.964

  • Liao, Y., Ivanova, L., Plumer, T., Zhu, H., Morris, E., Gurney, J., . . . Cairo, M. (2016). Human placental derived stem cell (HPDSCs) significantly improves the cutaneous manifestations in a mouse model of recessive dystrophic epidermolysis bullosa (RDEB). Experimental Hematology, 44(9), S87. doi:10.1016/j.exphem.2016.06.177

  • Luo, W., Xu, C., Ayello, J., Dela Cruz F., Rosenblum, J., Lessnick, S., & Cairo, M. (2016). Protein phosphatase 1 regulatory subunit 1A (PPP1R1A) promotes tumor growth and metastasis in ewing sarcoma. Pediatric Blood & Cancer, 63(Suppl S1), S71.

  • Majzner, R., Sandoval, C., Dozor, A. J., Jin, Z., van de Ven, C., Dalal, R., . . . Cairo, M. S. (2016). Pulmonary function after hematopoietic stem cell transplantation is significantly better in pediatric recipients following reduced toxicity compared with myeloablative conditioning. Bone Marrow Transplantation, 51(11), 1530-1532. doi:10.1038/bmt.2016.172

  • Mehta, B., Klejmont, L., Milone, M., Shaw, L., Morris, E., Abikoff, C., . . . Cairo, M. (2016). Pharmacokinetics and clinical outcomes of intravenous busulfan administered twice daily during conditioning in pediatric recipients prior to familial haploidentical (FHI) T-cell depleted (TCD) allogeneic hematopoietic stem cell transplantation (AlloHSCT) in high risk sickle cell disease (SCD). Pediatric Blood & Cancer, 63(Suppl S1), S17.  

  • Mehta, B., Militano, O., Ozkaynak, M. F., van de Ven, C., Nickerson, B. A., Hamby, C.,. . . Cairo, M. S. (2016). Mycophenolate mofetil (MMF) administered every eight hours with tacrolimus is efficacious in acute graft versus host disease (aGVHD) prophylaxis in childhood, adolescent and young adult (CAYA) allogeneic hematopoietic progenitor transplant (ALLOHPT) recip. Pediatric Blood & Cancer, 63(Suppl S1), S97.

  • Nash, M., Harrison, L., Shi, Q., El-Mallawany, N., Abikoff, C., Hochberg, J.,. . . Cairo, M. S. (2016). A pilot trial of unmatched human placental derived stem cells (HPDSCs) in conjunction with unrelated cord blood transplantation (UCBT) in children and young adults with malignant and non-malignant disease (IND 14949). Biology of Blood and Marrow Transplantation, 22(3), S143-S144. doi:10.1016/j.bbmt.2015.11.484

  • Pasquini, M. C., Zhang, M. J., Medeiros, B. C., Armand, P., Hu, Z. H., Nishihori, T., . . . Cairo, M. S. (2016). Hematopoietic cell transplantation outcomes in monosomal karyotype myeloid malignancies. Biology of Blood and Marrow Transplantation, 22(2), 248-257. doi:10.1016/j.bbmt.2015.08.024

  • Picoraro, J. A., Ovchinsky, N., Martinez, M., Lobritto, S. J., Satwani, P., Ramphal, R., . . . Cairo, M. S. (2016). First attempt of sequential living donor liver and hematopoietic stem cell transplantation in a child with advanced hepatocellular carcinoma: Case report. Transplantation Proceedings, 48(9), 3174-3177. doi:10.1016/j.transproceed.2016.09.002

  • Pinkerton, R., Cairo, M. S., & Cotter, F. E. (2016). Childhood, adolescent and young adult non-Hodgkin lymphoma: State of the science. British Journal of Haematology, 173(4), 503-504. doi:10.1111/bjh.14091

  • Talano, J., Abikoff, C., Moore, T. B., Weinberg, R. S., Braniecki, S., Chu, Y., . . . Cairo, M. S. (2016). Familial haploidentical (FHI) allogeneic stem cell transplantation utilizing CD34 enrichment and T cell addback in children, adolescents & adults with high-risk sickle cell disease. rapid engraftment, robust immune reconstitution, low-incidence of GVHD. Pediatric Blood & Cancer, 63(Suppl 1), S93-S94.

  • Tiwari, A. A., Ayello, J., Van De Ven, C., Kurien, L., Barth, M. J., & Cairo, M. S. (2016). Antibody drug conjugates (anti-CD79b-vc-MMAE, polatuzumab vedotin) exhibit enhanced cell death targeted to CD79b+ burkitt lymphoma (BL) and primary mediastinal large B-cell lymphoma (PMBL). Cancer Research, 76(14 (Suppl)), 579. doi:10.1158/1538-7445.AM2016-579

  • Zahler, S., Luo, W., Ayello, J., & Cairo, M. S. (2016). Engineering dendritic cell-based vaccines as targeted immunotherapy against medulloblastoma, neuroblastoma, and Ewing sarcoma. Cancer Research, 76(14 (Suppl)), 4913. doi:10.1158/1538-7445.AM2016-4913

  • Arora, M., Hemmer, M. T., Ahn, K. W., Klein, J. P., Cutler, C. S., Urbano-Ispizua, A., . . . Cairo, M. S. (2015). Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. Biology of Blood and Marrow Transplantation, 21(4), 640-645. doi:10.1016/j.bbmt.2014.10.022

  • Awasthi, A., Ayello, J., Van De Ven, C., Elmacken, M., Sabulski, A., Islam, H., . . . Cairo, M. S. (2015). Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20 rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): Potential targeted therapy in patients with poor risk CD20 BL and pre-B-ALL. British Journal of Haematology, 171(5), 763-775. doi:10.1111/bjh.13764

  • Bachanova, V., Burns, L. J., Ahn, K. W., Laport, G. G., Akpek, G., Kharfan-Dabaja, M. A., . . . Cairo, M. (2015). Impact of pretransplantation F-fluorodeoxy glucose-positron emission tomography status on outcomes after allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Biology of Blood and Marrow Transplantation, 21(9), 1605-1611. doi:10.1016/j.bbmt.2015.05.007

  • Bachanova, V., Burns, L. J., Wang, T., Carreras, J., Gale, R. P., Wiernik, P. H., . . . Cairo, M. S. (2015). Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. Bone Marrow Transplantation, 50(2), 197-203. doi:10.1038/bmt.2014.259

  • Boyiadzis, M., Arora, M., Klein, J. P., Hassebroek, A., Hemmer, M., Urbano-Ispizua, A., . . .Cairo, M. S. (2015). Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia. Clinical Cancer Research, 21(9), 2020-2028. doi:10.1158/1078-0432.CCR-14-0586

First Prev 1 2 3 4 5 Next Last